Category Archives: Other

Reviews that are lab-based (e.g. genes, pharmaceuticals) or on unique groups of people (e.g. fishermen, nurses)

Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: Meta-regression analysis of 12 clinical trials in 5168 patients

2009

Objectives: Tenofovir/emtricitabine (TDF/FTC) and abacavir/lamivudine (ABC/3TC) are widely used with ritonavir (RTV)-boosted protease inhibitors (PIs) as first-line highly active antiretroviral therapy (HAART), but there is conflicting evidence on their relative...

Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers

2013

Background: Extensive evidence shows that well over 50% of people prefer to be cared for and to die at home provided circumstances allow choice. Despite best efforts and policies, one-third...

Congregation-based programs to address HIV/AIDS: Elements of successful implementation

2011

Religious organizations may be uniquely positioned to address HIV by offering prevention, treatment, or support services to affected populations, but models of effective congregation-based HIV programs in the literature are...

Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure

2007

BACKGROUND: Populations such as healthcare workers (HCWs), injection drug users (IDUs), and people engaging in unprotected sex are all at risk of being infected with the human immunodeficiency virus (HIV)....

Interactions between protease inhibitors and acid-reducing agents: A systematic review

2007

OBJECTIVE: The purpose of this article is to provide a systematic review of the available pharmacokinetic and clinical data on drug interactions between protease inhibitors (PIs) and acid-reducing agents, and...

HIV risk behavior among adults with severe mental illness: A systematic review

2005

Adults with severe mental illness (SMI) have been disproportionately affected by the HIV/AIDS epidemic. This systematic review of the empirical literature on SMI documents the prevalence and correlates of HIV...

Baseline CD4+ cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy

2001

OBJECTIVE: To investigate the relationship between viral load suppression and baseline viral load as well as that between viral load suppression and baseline CD4(+) cell count. DESIGN: Meta-analysis of published...

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis

2000

Objective: To evaluate treatment-mediated changes in HIV-1 RNA and CD4 count as prognostic markers and surrogate end points for disease progression (AIDS/death). Methods: Data from 13,045 subjects in all 16...

Trends in overall opportunistic illnesses, Pneumocystis carinii pneumonia, cerebral toxoplasmosis and Mycobacterium avium complex incidence rates over the 30 years of the HIV epidemic: A systematic review

2014

BACKGROUND: The natural history of HIV infection has changed dramatically after the introduction of highly active antiretroviral therapy. Currently, opportunistic illnesses still represent a major cause of death and hospitalization...

Adherence to antiretroviral therapy and treatment outcomes among conflict-affected and forcibly displaced populations: A systematic review

2012

BACKGROUND: Optimal adherence to highly active antiretroviral therapy (HAART) is required to promote viral suppression and to prevent disease progression and mortality. Forcibly displaced and conflict-affected populations may face challenges...

Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: A systematic review and meta-analysis

2012

BACKGROUND: 100 million people worldwide are homeless; rates of mortality and morbidity are high in this population. The contribution of infectious diseases to these adverse outcomes is uncertain. Accurate estimates...

Monoclonal CCR5 antibody for treatment of people with HIV infection

2010

BACKGROUND: A monoclonal CCR5 antibody, PRO 140 (a humanised form of the PA14 antibody), inhibits CCR5-tropic (R5) HIV-1. This may be an effective new treatment for HIV-infected patients, with the...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!